These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35163644)

  • 1. GFP-Margatoxin, a Genetically Encoded Fluorescent Ligand to Probe Affinity of Kv1.3 Channel Blockers.
    Denisova KR; Orlov NA; Yakimov SA; Kryukova EA; Dolgikh DA; Kirpichnikov MP; Feofanov AV; Nekrasova OV
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Terminal Tagging with GFP Enhances Selectivity of Agitoxin 2 to Kv1.3-Channel Binding Site.
    Nekrasova OV; Primak AL; Ignatova AA; Novoseletsky VN; Geras'kina OV; Kudryashova KS; Yakimov SA; Kirpichnikov MP; Arseniev AS; Feofanov AV
    Toxins (Basel); 2020 Dec; 12(12):. PubMed ID: 33339256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AgTx2-GFP, Fluorescent Blocker Targeting Pharmacologically Important K
    Primak AL; Orlov NA; Peigneur S; Tytgat J; Ignatova AA; Denisova KR; Yakimov SA; Kirpichnikov MP; Nekrasova OV; Feofanov AV
    Toxins (Basel); 2023 Mar; 15(3):. PubMed ID: 36977120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complexes of Peptide Blockers with Kv1.6 Pore Domain: Molecular Modeling and Studies with KcsA-Kv1.6 Channel.
    Nekrasova OV; Volyntseva AD; Kudryashova KS; Novoseletsky VN; Lyapina EA; Illarionova AV; Yakimov SA; Korolkova YV; Shaitan KV; Kirpichnikov MP; Feofanov AV
    J Neuroimmune Pharmacol; 2017 Jun; 12(2):260-276. PubMed ID: 27640211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KcsA-Kv1.x chimeras with complete ligand-binding sites provide improved predictivity for screening selective Kv1.x blockers.
    Szekér P; Bodó T; Klima K; Csóti Á; Hanh NN; Murányi J; Hajdara A; Szántó TG; Panyi G; Megyeri M; Péterfi Z; Farkas S; Gyöngyösi N; Hornyák P
    J Biol Chem; 2024 Apr; 300(4):107155. PubMed ID: 38479597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Margatoxin-bound quantum dots as a novel inhibitor of the voltage-gated ion channel Kv1.3.
    Schwartz AB; Kapur A; Wang W; Huang Z; Fardone E; Palui G; Mattoussi H; Fadool DA
    J Neurochem; 2017 Feb; 140(3):404-420. PubMed ID: 27861889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Margatoxin is a non-selective inhibitor of human Kv1.3 K+ channels.
    Bartok A; Toth A; Somodi S; Szanto TG; Hajdu P; Panyi G; Varga Z
    Toxicon; 2014 Sep; 87():6-16. PubMed ID: 24878374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining mKate2-Kv1.3 Channel and Atto488-Hongotoxin for the Studies of Peptide Pore Blockers on Living Eukaryotic Cells.
    Orlov NA; Ignatova AA; Kryukova EV; Yakimov SA; Kirpichnikov MP; Nekrasova OV; Feofanov AV
    Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering-specific pharmacological binding sites for peptidyl inhibitors of potassium channels into KcsA.
    Legros C; Schulze C; Garcia ML; Bougis PE; Martin-Eauclaire MF; Pongs O
    Biochemistry; 2002 Dec; 41(51):15369-75. PubMed ID: 12484776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeras of KcsA and Kv1 as a bioengineering tool to study voltage-gated potassium channels and their ligands.
    Kudryashova KS; Nekrasova OV; Kirpichnikov MP; Feofanov AV
    Biochem Pharmacol; 2021 Aug; 190():114646. PubMed ID: 34090876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atto488-Agitoxin 2-A Fluorescent Ligand with Increased Selectivity for Kv1.3 Channel Binding Site.
    Denisova KR; Orlov NA; Yakimov SA; Kirpichnikov MP; Feofanov AV; Nekrasova OV
    Bioengineering (Basel); 2022 Jul; 9(7):. PubMed ID: 35877346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescent system based on bacterial expression of hybrid KcsA channels designed for Kv1.3 ligand screening and study.
    Kudryashova KS; Nekrasova OV; Kuzmenkov AI; Vassilevski AA; Ignatova AA; Korolkova YV; Grishin EV; Kirpichnikov MP; Feofanov AV
    Anal Bioanal Chem; 2013 Mar; 405(7):2379-89. PubMed ID: 23307127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of the Kv1.1 Channel with Peptide Pore Blockers: A Fluorescent Analysis on Mammalian Cells.
    Orlov NA; Kryukova EV; Efremenko AV; Yakimov SA; Toporova VA; Kirpichnikov MP; Nekrasova OV; Feofanov AV
    Membranes (Basel); 2023 Jul; 13(7):. PubMed ID: 37505011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial pore blocker acts specifically on voltage-gated potassium channel isoform K
    Gigolaev AM; Lushpa VA; Pinheiro-Junior EL; Tabakmakher VM; Peigneur S; Ignatova AA; Feofanov AV; Efremov RG; Mineev KS; Tytgat J; Vassilevski AA
    J Biol Chem; 2022 Nov; 298(11):102467. PubMed ID: 36087839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding modes of two scorpion toxins to the voltage-gated potassium channel kv1.3 revealed from molecular dynamics.
    Chen R; Chung SH
    Toxins (Basel); 2014 Jul; 6(7):2149-61. PubMed ID: 25054783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of
    Naseem MU; Tajti G; Gaspar A; Szanto TG; Borrego J; Panyi G
    Front Pharmacol; 2021; 12():733610. PubMed ID: 34658872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptidyl inhibitors of shaker-type Kv1 channels elicit twitches in guinea pig ileum by blocking kv1.1 at enteric nervous system and enhancing acetylcholine release.
    Suarez-Kurtz G; Vianna-Jorge R; Pereira BF; Garcia ML; Kaczorowski GJ
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1517-22. PubMed ID: 10336547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear localization and functional characteristics of voltage-gated potassium channel Kv1.3.
    Jang SH; Byun JK; Jeon WI; Choi SY; Park J; Lee BH; Yang JE; Park JB; O'Grady SM; Kim DY; Ryu PD; Joo SW; Lee SY
    J Biol Chem; 2015 May; 290(20):12547-57. PubMed ID: 25829491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kv1.3 channels regulate synaptic transmission in the nucleus of solitary tract.
    Ramirez-Navarro A; Glazebrook PA; Kane-Sutton M; Padro C; Kline DD; Kunze DL
    J Neurophysiol; 2011 Jun; 105(6):2772-80. PubMed ID: 21430270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-proliferative effect of Kv1.3 blockers in A549 human lung adenocarcinoma in vitro and in vivo.
    Jang SH; Choi SY; Ryu PD; Lee SY
    Eur J Pharmacol; 2011 Jan; 651(1-3):26-32. PubMed ID: 21087602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.